Press Releases

Valberedningens ledamöter inför Ziccums årsstämma 2025 har nu utsetts. Ziccums valberedning inför årsstämman 2025 har tillsatts i enlighet med instruktionen för valberedningen som beslutades av årsstämman...

Ziccum AB (publ) (‘Ziccum’) has an ongoing project with Copenhagen University to engineer inhalable solid dosage forms of mRNA/LNP. At the production stage, all primary development objectives have been met. The project has reached the phase...

Ziccum AB (publ) (”Bolaget”) avhöll den 12 november 2024 extra bolagsstämma i Lund. Vid stämman fattades bland annat följande beslut. Ändring av bolagsordningenStämman beslutade, i enlighet med styrelsens förslag...

The following main resolutions were passed at the extraordinary general meeting (the “EGM”) of Ziccum AB (publ) (the “Company”) on 12 November 2024 in Lund. Amendment of the articles of associationThe EGM resolved, in accordance...

Watch Ziccum’s CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid in Swedish on the highlights of Ziccum’s Q3 2024 report and the company’s current status. Ziccum’s CEO, Ann Gidner, shares a number of exciting...

The three Ziccum AB (publ) (‘Ziccum’) patent application families advanced to international Patent Cooperation Treaty (PCT) stage in April 2024 will now be published. As of 31 October 2024, the PCT applications will be available for consultation...

INTERIM REPORT Q3, 1 JULY – 30 SEPTEMBER 2024 Significant events after Q3 2024 On October 10, The Board of Directors of Ziccum AB (publ) (“Ziccum” or the “Company”) announced its intention to carry out a new issue of shares...

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. N.B., Notice of the extraordinary general meeting of Ziccum AB (publ) on 8 November 2024 was published through a press...

OBS. Kallelse till extra bolagsstämma i Ziccum AB (publ) den 8 november 2024 offentliggjordes genom pressmeddelande den 10 oktober 2024. Av administrativa skäl har beslutats att ändra datum för den aviserade extra bolagsstämman...

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of Ziccum AB (publ), reg. no. 559107-9412, (the “Company”) are hereby given notice to attend...

Aktieägarna i Ziccum AB (publ), org. nr 559107-9412, (”Bolaget”) kallas härmed till extra bolagsstämma den 8 november 2024 kl. 15.00 i Bolagets lokaler på Scheelevägen 22 i Lund. Rösträttsregistrering startar...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, HELT ELLER DELVIS, DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER I NÅGON...

Ziccum AB (publ) hereby announces that the company has retained Vator Securities AB (“Vator Securities”) to serve as its Certified Adviser. The appointment of Vator Securities as Ziccum's Certified Adviser (CA) shall come into effect on September...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

Ziccum is pleased to announce that the appellation of its proprietary technology, LaminarPace, has been officially registered with the United States Patent and Trademark Office (USPTO) as a trademark since 23 July 2024. Obtaining trademark protection...

Watch Ziccum CEO Ann Gidner in a comprehensive interview in Swedish with analyst Jonathan Furelid on the highlights of Ziccum’s Q2 2024 report and the company’s current and coming status. CEO Ann Gidner provides investors with updates and...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

INTERIM REPORT Q2, 1 JANUARY – 30 JUNE 2024 Significant events during Q2 2024 Ziccum strengthens and streamlines business and finance functionsOn April 3, the company announced that it is reorganizing its administrative functions, due to the increased...

Ziccum AB (publ) announces important findings on an increase in mRNA drug activity after LaminarPace treatment and the investigations of the potential mechanisms behind this effect, including the development of a new, unique analytical method to generate...